Daewoong's P-CAB Contender Holds Up Well At Phase III

Non-Inferior To Esomeprazole

 
• By Jung Won Shin

South Korean firm presents encouraging Phase III data for its novel P-CAB drug fexuprazan at Digestive Disease Week and hopes the results will accelerate entry into global markets.   

Digestive_System
Daewoong Aims To Position Fexuprazan As Best-In-Class GERD Option • Source: Shutterstock

More from South Korea

More from Focus On Asia